drugset / Trial / NCT00337285
An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the long-term safety and efficacy of three NRP104 doses of 30 mg, 50 mg, or 70 mg, administered at the same time daily, in the treatment of adults with ADHD.
Timeline
- Start
- 2006-07
- Primary completion
- 2007-11
- Completion
- 2008-06
Publications
- Results Ginsberg L, Katic A, Adeyi B, Dirks B, Babcock T, Lasser R, Scheckner B, Adler LA. Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity. Curr Med Res Opin. 2011 Jun;27(6):1097-107. doi: 10.1185/03007995.2011.567256. Epub 2011 Mar 28.
- Results Mattingly G, Weisler R, Dirks B, Babcock T, Adeyi B, Scheckner B, Lasser R. Attention deficit hyperactivity disorder subtypes and symptom response in adults treated with lisdexamfetamine dimesylate. Innov Clin Neurosci. 2012 May;9(5-6):22-30.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lisdexamfetamine | Other / unclassified | 30 mg | Oral |
| Subject | Lisdexamfetamine | Other / unclassified | 50 mg | Oral |
| Subject | Lisdexamfetamine | Other / unclassified | 70 mg | Oral |